KLOW (TB-500 + BPC-157 + KPV + GHK-Cu) (80mg)
KLOW is a research blend of four peptides: TB-500 (10 mg), BPC-157 (10 mg), KPV (10 mg), and GHK-Cu (50 mg) — a total of 80 mg per vial. The quadruple combination aims for synergistic regenerative action, anti-inflammatory regulation via NF-κB inhibition, and support for collagen/elastin synthesis. It is administered subcutaneously once daily with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Four peptides with complementary mechanisms of action: **TB-500** (Thymosin Beta-4, 43 amino acids) regulates actin, promoting angiogenesis, cell migration, and fibrosis reduction via PI3K/Akt and Notch pathways. **BPC-157** (a pentadecapeptide) enhances VEGF/PDGF signaling and NO pathways, accelerating the healing of tendons, muscles, ligaments, and intestinal injuries. **KPV** (Lys-Pro-Val, a tripeptide from α-MSH) inhibits NF-κB signaling, reducing inflammatory cytokines (TNF-α, IL-6, IL-1β) without immunosuppression. **GHK-Cu** (a tripeptide-copper complex) acts as a genomic modulator, activates tissue growth genes, stimulates collagen/elastin/glycosaminoglycan synthesis, and exhibits antioxidant properties.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~26.7 mg/mL total (TB/BPC/KPV ≈ 3.33 mg/mL · GHK-Cu ≈ 16.7 mg/mL).
- Typical daily range: 250–750 mcg TB/BPC/KPV + 1.25–3.75 mg GHK-Cu (gradual titration).
- Easy measurement: At 26.7 mg/mL, 1 unit = 0.01 mL ≈ 267 mcg total (33.3 mcg TB/BPC/KPV + 166.7 mcg GHK-Cu).
- Storage: Lyophilized: freezer at −20 °C · after reconstitution: refrigerator at 2–8 °C · use within 14–28 days.
12-Week Gradual Titration (3 mL = ~26.7 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 250 mcg TB/BPC/KPV + 1.25 mg GHK-Cu (2.0 mg total) | 4.7 Units (0.05 mL) |
| Weeks 3–4 | 500 mcg TB/BPC/KPV + 2.5 mg GHK-Cu (4.0 mg total) | 9.4 Units (0.09 mL) |
| Weeks 5–8 | 750 mcg TB/BPC/KPV + 3.75 mg GHK-Cu (6.0 mg total) | 14.1 Units (0.14 mL) |
| Weeks 9–12 (Maintenance) | 500 mcg TB/BPC/KPV + 2.5 mg GHK-Cu (4.0 mg total) | 9.4 Units (0.09 mL) |
Studies report administration once daily subcutaneously. Gradual titration for 8–12 weeks; the maintenance phase (weeks 9–12) reduces the dose for a gradual taper. 30–50 unit syringes offer better accuracy for initial low doses (<10 units).
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water with a sterile syringe (ideally a 3 mL syringe with a 21–23 gauge needle).
- Slowly inject down the side of the vial; avoid foaming (do not spray directly onto the powder).
- Gently swirl or rotate until fully dissolved (do not shake vigorously — GHK-Cu may impart a slightly bluish color due to the copper, this is normal).
- Note the date of reconstitution; refrigerate at 2–8 °C, protecting from light.
Protocol Overview
- Objective: Comprehensive tissue repair, inflammation reduction, and regeneration via quadruple peptide action.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16 if needed), with a maintenance phase.
- Storage: Lyophilized frozen · reconstituted refrigerated · use within 14–28 days.
Dosing Protocol
- Initiation: 7.5 units/day (0.075 mL) — low dose to assess individual tolerance.
- Titration: 15 units wks 3–4 → 22.5 units wks 5–8 (maximum dose).
- Maintenance: 15 units wks 9–12 — gradual taper.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 8–12 weeks on · optional extension to 16 weeks.
- Break between cycles: After the cycle, a washout period of 4–6 weeks is recommended. This pause prevents tolerance to the blend's active ingredients.
Washout & Cycle Restart
When can I restart?
After the cycle, a washout period of 4–6 weeks is recommended. This pause prevents tolerance to the blend's active ingredients.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C or lower in dry, dark conditions.
- Reconstituted: 2–8 °C · use within 14–28 days · avoid freeze-thaw cycles.
- Allow frozen vials to reach room temperature before opening.
Important Notes
- The slightly bluish color after reconstitution is normal (GHK-Cu = copper).
Potential Benefits & Side Effects
Potential Benefits:
- Accelerated healing through multiple mechanisms — angiogenesis, cell migration, collagen synthesis.
- Potent anti-inflammatory action via NF-κB inhibition (KPV) without immunosuppression.
- Enhanced collagen/elastin synthesis (GHK-Cu) — supports skin, joints, and tissues.
- Angiogenesis and improved blood flow to injured tissues.
- Musculoskeletal health support — ideal for athletic injuries.
Potential Side Effects:
- Possible mild injection site reaction (redness, itching).
- Rare mild dizziness due to vasodilation (TB-500/GHK-Cu).
- Limited human clinical data for the quadruple combination.
- Long-term safety has not been fully established.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Immunosuppression with chronic use
KPV (α-MSH fragment) is strongly anti-inflammatory. Theoretical risk of reduced immune surveillance with long-term use. No clinical studies in humans.
📄 FEBS Lett 2005Angiogenesis & tissue remodeling
GHK-Cu promotes angiogenesis, tissue regeneration, and increases collagen/elastin. Theoretical concern for enhancing existing tumors, though no clinical signal exists.
📄 Life Sci 2012References
- Thymosin β4 Accelerates Wound Healing: Primary Mechanism — Thymosin β4 accelerates healing: primary mechanism
View Source - BPC-157 in Orthopaedic Sports Medicine: Systematic Review — HSS Journal (2025) — BPC-157 in orthopaedic sports medicine: systematic review (2025)
View Source - KPV Tripeptide: Anti-Inflammatory Action in Colitis Models (PMC) — KPV tripeptide: anti-inflammatory action in colitis models
View Source - Int J Mol Sci (MDPI) — GHK-Cu: regenerative and antioxidant properties
View Source - Frontiers in Endocrinology (2021) — Progress in the function and application of Thymosin β4
View Source
External Sources & Regulatory Status
Regulatory Approvals
Compounded blend — Not evaluated as a standalone medicine
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →